Install
Research & Evidence
Trial design, systematic reviews, medical statistics, and guideline updates.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research & Evidence
Beyond Outreach: Structural Drivers of Representation in Clinical Trials
28+ min ago (901+ words) The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened. Participant burden and access issues are believed to be the biggest challenges in advancing representation in clinical…...
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
8+ hour, 40+ min ago (209+ words) BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the treatment of patients with…...
Liquid Radioembolic Aims Radiation Directly at Brain Tumors Via Their Own Blood Supply
1+ hour, 54+ min ago (662+ words) Mount Sinai and Johnson & Johnson will collaboratively evaluate an investigational liquid radioembolic that combines Iodine-131 with TRUFILL n-BCA to embolize and irradiate brain tumors through their own blood supply, starting with meningiomas....
Translumina SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
5+ hour, 33+ min ago (264+ words) Corporate | 12 October 2026 20:05 Translumina / Key word(s): Miscellaneous SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease 12.10.2026 / 20:05 CET/CEST The issuer is solely responsible for the content of this announcement. As one of…...
Pasatru Demonstrates Zero New Heterotopic Ossification Lesions in Adult Fibrodysplasia Ossificans Progressiva Patients During OPTIMA Trial Extension
7+ hour, 8+ min ago (389+ words) Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and…...
Givaudan to Reveal New Metabolic Health Botanical at SupplySide Global 2026
3+ hour, 59+ min ago (186+ words) The company plans to unveil a clinically studied ingredient on opening day and host a longevity session alongside its cognitive, mobility, and metabolic health portfolio. Givaudan announced it will highlight metabolic health and longevity, including the reveal of a new…...
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
5+ hour, 26+ min ago (168+ words) 12 Oct, 2026, 21:02 IDT As one of the contemporary multinational randomized DCB trials undertaken to date, SPARX is expected to generate the evidence needed to define the future role of drug-coated balloons in complex coronary intervention. Addressing an Unmet Clinical Need Prof....
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
7+ hour, 1+ min ago (110+ words) Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia October 12, 2026 8:30 AM EDT Andrew McKibben - Senior Vice President, Strategic Finance & Investor RelationsChristopher Peetz - CEO & DirectorRob Myers - Chief Medical OfficerPeter Radovich - COO & President Good…...
Data on PDE9 inhibition in HF mixed; more research planned
7+ hour, 33+ min ago (473+ words) PHOENIX — Tovinontrine increased plasma cyclic guanosine monophosphate levels in patients with HF with reduced or preserved ejection fraction but did not change N-terminal pro-B-type natriuretic peptide levels, a speaker reported. A post hoc analysis of data indicated a possible inverse…...
Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
6+ hour, 42+ min ago (205+ words) Pune, India, October 6th, 2026, FinanceWire This is a paid advertisement. The Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS. The randomized, double-blind, placebo-controlled study is designed to evaluate clinical and radiological…...